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Abstract
Background: Rett syndrome (RTT) is one of the most prevalent neurodevelopmental disorders in females, caused
by de novo mutations in the X-linked methyl CpG-binding protein 2 gene, MECP2. Although abnormal regulation of
neuronal genes due to mutant MeCP2 is thought to induce autistic behavior and impaired development in RTT
patients, precise cellular mechanisms underlying the aberrant neural progression remain unclear.
Results: Two sets of isogenic pairs of either wild-type or mutant MECP2-expressing human induced pluripotent
stem cell (hiPSC) lines were generated from a single pair of 10-year-old RTT-monozygotic (MZ) female twins. Mutant
MeCP2-expressing hiPSC lines did not express detectable MeCP2 protein during any stage of differentiation. The lack
of MeCP2 reflected altered gene expression patterns in differentiated neural cells rather than in undifferentiated
hiPSCs, as assessed by microarray analysis. Furthermore, MeCP2 deficiency in the neural cell lineage increased
astrocyte-specific differentiation from multipotent neural stem cells. Additionally, chromatin immunoprecipitation
(ChIP) and bisulfite sequencing assays indicated that anomalous glial fibrillary acidic protein gene (GFAP) expression
in the MeCP2-negative, differentiated neural cells resulted from the absence of MeCP2 binding to the GFAP gene.
Conclusions: An isogenic RTT-hiPSC model demonstrated that MeCP2 participates in the differentiation of neural
cells. Moreover, MeCP2 deficiency triggers perturbation of astrocytic gene expression, yielding accelerated astrocyte
formation from RTT-hiPSC-derived neural stem cells. These findings are likely to shed new light on astrocytic
abnormalities in RTT, and suggest that astrocytes, which are required for neuronal homeostasis and function,
might be a new target of RTT therapy.
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Background
Rett syndrome (RTT; MIM 312750) is a representative
X-linked neurodevelopmental disease distinguished by
repetitive and stereotypic hand movements replacing pur-
poseful hand use, accompanied by gait ataxia, seizures,
and autistic features. Patients present with apparently
normal psychomotor development during the first 6–18
months of life, followed by a short period of developmen-
tal stagnation, and then rapid disease progression with the
characteristic features described above [1]. The incidence
of RTT is 1 in 10,000–15,000 female births [2,3]. A linkage
analysis demonstrated that the region harboring a causa-
tive gene is located between Xq27 and Xqter [4]. Mean-
while, a mutation analysis identified an X-linked gene
encoding methyl-CpG-binding protein 2 (MeCP2) in the
Xq28 region as the cause of RTT, where > ~95% of
patients with a classic RTT phenotype carry the MECP2
mutation [5,6].
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MeCP2 is a transcription repressor that inhibits tran-
scription by binding to methylated CpG dinucleotides,
and also by recruiting co-repressors and chromatin re-
modeling proteins [7]. Thus, mutant MeCP2 affects
large-scale chromatin organization [8], resulting in the
mal-regulation of a number of genes, including neural
and synaptic genes [9-13]. Furthermore, because RTT is
an X-linked dominant disorder, phenotypic differences
between female RTT patients have generally been attrib-
uted to variances in X chromosome inactivation (XCI)
patterns, with skewing in favor of the mutant allele for
the more severe clinical phenotypes [14-16].
Nevertheless, it remains unknown how developmental
defects occur in the RTT brain at the cellular level. Re-
cently, human induced pluripotent stem cell (hiPSC)
technology has facilitated the modeling of neurological
diseases by permitting the reprogramming of somatic
cells into pluripotent cells [17]. So far, several studies
have been performed with hiPSCs derived from patients
with RTT and other neurological and neurodevelopmental
diseases [18-26]. Previous reports of differentiated cells
derived from RTT patient-specific hiPSCs demon-
strated several abnormal in vitro phenotypes, such as
diminished cell soma and nuclear sizes, reduced ex-
pression of neuronal markers, and attenuated dendritic
spine density [19,21-24].
We recently reported a rare monozygotic (MZ) case of
RTT in twins in which the genomic sequences were
identical, including a MECP2 frame-shift mutation
(G269AfsX288) [27]. Interestingly, the patients (desig-
nated the RTT-MZ twins) showed divergent symptom
severity regarding impaired neurological development,
despite an identical genomic structure. Taking advantage
of the nonrandom pattern of XCI in female hiPSCs [23]
and the shared genetic background of the RTT-MZ
twins [27], we aimed to generate two sets of isogenic
pairs of wild-type MECP2- and mutant MECP2-express-
ing hiPSC lines from the RTT-MZ individuals. We then
went on to show detailed defects in neural cells related
to MeCP2 protein deficiency-induced developmental
defects in RTT. Furthermore, we set out to clarify
whether epigenetic and environmental cues participate
in the abnormal neural development of RTT patients
by comparison of the RTT-hiPSC lines derived from
the RTT-MZ twin patients, who presented with varying
symptom severity.
Results
Mosaic expression patterns in fibroblasts procured from
RTT-MZ twins
We recently established fibroblast cell lines from the
RTT-MZ twins (patients RS1 and RS2). These RTT
twins have a de novo frame-shift mutation in exon 4
(c.806delG) that truncates the MeCP2 protein within the
transcriptional repression domain (Fig. 1A). We also re-
ported that fibroblasts generated from both patients ex-
hibited random XCI patterns [27], which were detected
by the methylation-specific polymerase chain reaction
(PCR)-based HUMARA (human androgen receptor)
XCI assay [28]. To examine the expression patterns of
MeCP2 in RS1 and RS2 fibroblasts, immunostaining was
performed with a specific primary antibody against
MeCP2. Consequently, the fibroblast lines derived from
the RTT-MZ twins included both MeCP2-positive and
MeCP2-negative cells (Fig. 1B). Such mosaic expression
patterns for the MeCP2 suggests that the fibroblasts
comprise MeCP2-positive cells with the X chromosome
harboring wild-type MECP2 as the active MeCP2 species,
and MeCP2-negative cells with the X chromosome har-
boring mutant MECP2 as the active MeCP2 species. The
fractions of MeCP2-positive cells among the RS1 and RS2
fibroblasts were 0.64 and 0.60, respectively (Fig. 1C).
Generation and characterization of RTT-MZ hiPSC lines
We utilized standard methods and transduction of OCT4-,
SOX2-, KLF4-, and c-MYC-containing retroviruses to re-
program fibroblasts derived from the RTT-MZ twins into
RTT-hiPSCs. Each RTT-hiPSC clone was clonally isolated
and selected by morphological criteria and transgene silen-
cing. We also verified pluripotency of the stem cells by im-
munostaining of the hiPSCs with primary antibodies
against pluripotency markers (NANOG, OCT4, and
TRA-1-81) (Fig. 2A and Additional file 1A).
Fig. 1 MECP2 mutation in MZ twins with RTT and MeCP2 expression
pattern in RTT fibroblasts. (A) Schematic representation of MECP2 gene
structure and location of the MECP2 mutation. Direct sequencing of the
four coding exons in the MECP2 gene detected a guanine deletion at
position 806 (806delG) [27]. (B) Immunostaining for MeCP2 (red) and
phalloidin (green) along with Hoechst staining (blue) of wild-type
MECP2- and mutant MECP2-expressing fibroblasts. Scale bar, 100 μm.
(C) Fraction of MeCP2-positive cells among wild-type MECP2- and
mutant MECP2-expressing fibroblasts (n = 5 experiments; > 500
Hoechst-positive cells per experiment; *p < 0.05). WT, wild-type
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To evaluate in vivo pluripotency, we injected the RTT-
hiPSCs into the testes of immunodeficient mice, and con-
firmed the formation of teratomas containing derivatives
of all three embryonic germ layers (Additional file 1B).
No abnormalities were found in the karyotypes of any
of the hiPSC lines (Additional file 1C). Notably, most
of the selected hiPSC clones were either all MeCP2-
positive or MeCP2-negative, and putatively originated
from a single MeCP2-positive or MeCP2-negative fibro-
blast (Fig. 2A). Therefore, we isolated both wild-type
MECP2-expressing (RS1-52 M and RS2-65 M) and mu-
tant MECP2-expressing (RS1-61P and RS2-62P) clones
from each patient (RS1 and RS2) to generate four hiPSC
lines.
We next analyzed the XCI patterns in the hiPSC lines,
and found that the maternal X chromosome was active
in the MeCP2-positive (RS1-52 M and RS2-65 M)
clones, while the paternal X chromosome was active in
the MeCP2-negative (RS1-61P and RS2-62P) clones
(Fig. 2B). Although we isolated several clones that par-
tially include iPS cells with two active X chromosomes,
we only used clones with an inactive X chromosome
(i.e., the “standard” XCI status of undifferentiated hiPSCs
[29]) in the present study.
Our previous study [27] revealed that the maternally-
derived X chromosome carries the wild-type MECP2
allele, whereas the paternally-derived X chromosome
carries the mutant MECP2 allele. These results were
shown by sequencing the MECP2 gene in somatic
hybrid cell clones carrying either the maternal or the
paternal X chromosome of the RTT-MZ twins. Ac-
cordingly, the RS1-52 M and RS2-65 M hiPSC lines, in
which maternal wild-type MECP2 was preferentially
active, exhibited MeCP2 expression in the nuclei,
whereas the RS1-61P and RS2-62P hiPSC lines, in
which paternal mutant MECP2 was preferentially active,
did not (Fig. 2A).
MeCP2 expression in neural cells differentiated from
RTT-hiPSCs
We next differentiated the four RTT-hiPSC lines into
neural cells and examined MeCP2 expression in the pro-
geny. Immunostaining revealed that all of the cells derived
from the RS1-52 M and RS2-65 M hiPSC lines (containing
preferentially active maternal wild-typeMECP2) expressed
MeCP2 in the nucleus, like the parental hiPSCs. In par-
ticular, MAP2-positive neurons expressed MeCP2 more
strongly than glial fibrillary acidic protein (GFAP)-positive
astrocytes (Fig. 3A) as previously shown in mice [30,31].
However, no MeCP2 expression was found in the progeny
of the RS1-61P and RS2-62P hiPSC lines (containing pref-
erentially active paternal mutant MECP2), or in the nu-
cleus of RS1-61P/RS2-62P hiPSC-derived MAP2-positive
neurons or GFAP-positive astrocytes (Fig. 3A). Therefore,
neural cells differentiated from the RTT-hiPSC lines ap-
parently retain the XCI status of the undifferentiated cells.
Fig. 2 hiPSC lines and XCI patterns derived from the RTT-MZ twins. (A) MeCP2 (red) and OCT4 (green) expression in hiPSC lines derived from the
RTT-MZ twins. Scale bar, 150 μm. (B) XCI patterns in the four hiPSC lines, as assessed by the methylation-specific PCR-based HUMARA assay. Xi, X
inactivation pattern based on the inactive X chromosome; Xa, X inactivation pattern based on the active X chromosome; Xm, X chromosome
inherited from the mother; Xp, X chromosome inherited from the father
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Global gene expression in RTT-hiPSCs and differentiated
neural cells
We next investigated whether the loss of MeCP2 protein
affects the transcriptional network in undifferentiated
hiPSCs and neural progeny differentiated from RTT-
hiPSCs. Global gene expression levels in wild-typeMECP2-
and mutant MECP2-expressing cells were examined by
comparative microarray analyses of undifferentiated
hiPSCs and differentiated neural cells. The gene expression
data were normalized and subjected to principal compo-
nent analysis (PCA) and hierarchical clustering, with
the exception of those genes with low expression in all
samples.
The samples were clustered into hiPSC or neural cell
(N) groups depending on the MECP2 expression pattern.
In the PCA analysis, the original hiPSCs were clustered
tightly into one region, signifying few differences from
one hiPSC clone to the next. On the other hand, the
neural cells were roughly clustered into two groups that
reflected the status of the activated X chromosome
(Fig. 3B and Additional file 2). Next, we constructed
scatter plots to compare wild-type MECP2- and mutant
MECP2-expressing cells. In the undifferentiated hiPSCs,
the correlation coefficient (R2) was > 0.99 for any pair of
hiPSC clones. However, in the differentiated neural cells,
higher correlations (R2 > 0.98) were only found in com-
parisons of hiPSCs with the same XCI pattern (i.e., pa-
ternal X vs. paternal X or maternal X vs. maternal X),
while lower correlations (R2 < 0.98) were only found in
comparisons of hiPSCs with different XCI patterns (pa-
ternal X vs. maternal X) (Fig. 3C). The clustering den-
drogram (Additional file 3A) also showed that global
gene expressions for all four RTT-hiPSC clones during
the undifferentiated stage. After this time, mutant
MECP2-expressing hiPSCs became distinguishable from
wild-type MECP2-expressing hiPSCs due to neural dif-
ferentiation. Nevertheless, Tanaka et al. [25] recently
characterized five patient-speific cell lines with different
mutations to show that hiPSCs with MECP2 gene muta-
tions are distinguishable from normal hiPSCs and ESCs
even during the undifferentiated stage. By contrast, our
isogenic cell lines might largely exclude the effect of
Fig. 3 Immunostaining of neural cells derived from RTT-hiPSCs and gene expression analysis of hiPSC-derived neural cells. (A) Immunostaining
was performed to evaluate expression levels of MeCP2 (red), the neuronal marker, MAP2 (green), and the astrocytic marker, GFAP (magenta) in
RTT-hiPSC-derived neural cells. Ho, Hoechst (blue). Arrowhead indicated MAP2, MeCP2 and Hoechst positive cells. Scale bar, 50 μm. (B) Results of
PCA (performed by using MeV software (TIGR) Software) of microarray gene expression in RTT-hiPSC lines and neural cells differentiated
from RTT-hiPSC lines. N, neural cells differentiated from hiPSC lines. (C) Scatter plots of microarray gene expression in hiPSC-RTT lines and
neural cells differentiated from hiPSC-RTT lines. Neural cells were co-cultured for ~30 days with mouse astrocytes
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donor divergence, permitting the elucidation of MECP2
function during neural differentiation. While Tanaka and
colleagues [25] demonstrated that the gene expression of
a key mitochondrial transcription factor, NR3C1, was
upregulated in mutant MECP2-expressing cells after
neuronal differentiation, we failed to detect such a differ-
ence in the current study (Additional file 3B). These re-
sults suggest that MeCP2 plays a more important role as
a transcriptional regulator in differentiated neural cells
than in undifferentiated hiPSCs.
Enhanced astrocytic differentiation of mutant MECP2-
expressing neural stem cells derived from RTT-hiPSCs
Previous studies revealed that MeCP2 is involved in the
regulation of astroglial gene expression [32-34]. Gfap
and S100β are expressed at significantly higher levels in
astrocytes derived from MeCP2-null mouse embryonic
stem cells than in those derived from wild type mouse
embryonic stem cells [35,36]. Moreover, a truncated
form of RTT-associated MeCP2 (R168X) is reported to
be unable to promote neuronal differentiation in mice,
and instead promotes an abnormally high degree of
astrocytic differentiation [37]. We characterized neuro-
spheres derived from the four RTT-hiPSC lines (RS1-
61P, RS2-62P, RS1-52 M, and RS2-65 M), and found no
significant differences in neurosphere number, size, or
expression of neural stem cell markers between the two
groups derived from mutant vs. wild-type MECP2-ex-
pressing hiPSCs (Additional file 4). Next, the neuro-
spheres were differentiated into neural cells by using an
adhesion culture method without fibroblast growth
factor-2 (FGF-2) at ~30 days in vitro (Fig. 4A). The dif-
ferentiated cells were classified by their expression of
βIII-tubulin and GFAP. Immunocytochemical analysis
revealed that the neural cells originating from MeCP2-
negative hiPSC lines (RS1-61P and RS2-62P) contained
significantly higher proportions of GFAP-positive cells
than those originating from MeCP2-positive hiPSC lines
(RS1-52 M and RS2-65 M) (Fig. 4B). Most of the GFAP-
positive cells failed to express neuronal markers; therefore,
we concluded that these cells were in fact astrocytes.
During the neural development of the mammalian
central nervous system (CNS), neural stem cells ini-
tially differentiate into neurons, followed by astrocytes
and oligodendrocytes at a later stage. We and others re-
ported that MeCP2 binds to the promoter region of
astrocyte-specific genes, including S100β and Gfap, to
inhibit the conversion of neurons into astrocytes in
Fig. 4 Comparison of acquired neuronal and astrocytic properties between MeCP2-positive and negative hiPSC-derived neural cells. (A) Immunostaining
images of neural cells. Double labeling for GFAP (red) and βIII-tubulin (green) is shown along with Hoechst staining (Ho, blue) in RS1-52 M,
RS1-61P, RS2-65 M, and RS2-62P RTT-hiPSC-derived neurons. Scale bar, 200 μm. (B) Fraction of GFAP-positive cells relative to Hoechst-positive
cells in neural cells differentiated from RTT-hiPSC lines. (C) A qPCR-facilitated comparison of gene expression for astrocytic markers (GFAP, S100β) and
neuronal markers (TUBB3, MAP2) in neural cells differentiated from RTT-hiPSC lines. Relative gene expression levels were normalized to that of ACTB.
Data in (B) and (C) were analyzed by Student’s t-test and Welch’s t-test (*p < 0.05)
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mammals [33,34,37-39]. To determine how MeCP2-
regulated astrocyte-specific genes are influenced by the
absence of MeCP2, we next examined the expression of
S100β and GFAP in MeCP2-negative and McCP2-positive
neural cells. As a result, MeCP2-negative RS1-61P and
RS2-62P neural cells showed significantly enhanced ex-
pression of the astrocyte-specific genes, GFAP and S100β
(Fig. 4C). However, decreased expression levels of the
neuronal genes, TUBB3 and MAP2, were observed in
several samples (i.e., TUBB3 in RS2-62P cells and
MAP2 in RS1-61 cells) (Fig. 4C). These observations
suggest that MeCP2 deficiency in the neural cell lineage
increases astrocytic differentiation from multipotent
neural stem cells.
Lack of MeCP2 binding to the GFAP gene in RTT-hiPSC-
derived neural stem cells
MeCP2 was previously reported to bind to the highly
methylated exon 1 region of the Gfap gene in mouse
neurons [33,38]. To confirm these results in wild-type or
mutant MECP2-expressing neurospheres, we performed
chromatin immunoprecipitation (ChIP) assays with a
specific primary antibody against MeCP2. Binding data
were quantitated via real-time PCR by using primers
spanning from the STAT3 binding site within the GFAP
promoter to exon 1, relative to the transcription start
site of GFAP (Fig. 5A, indicated by blue bidirectional
arrows). For both the STAT3 binding site and GFAP
exon 1, precipitated genomic fragments were scarcely
detectable by quantitative PCR (qPCR) in neurospheres
derived from mutant MECP2-expressing hiPSC lines
(RS1-61P, RS2-62P), while significant precipitation of
genomic fragments was detected in neurospheres de-
rived from wild-type MECP2-expressing hiPSC lines
(RS1-52 M and RS2-65 M) (Fig. 5B).
Based on these results, we hypothesized that the in-
creased expression of GFAP was induced by lack of direct
MeCP2 binding to the GFAP gene in the mutant MECP2-
expressing cells. However, it is possible that MeCP2 dys-
function indirectly enhanced the maturation of neural
stem cells with truncated MeCP2, accompanied by de-
creased methylation of gfap [33], which might in turn
modify MeCP2 protein recruitment. Thus, we performed
bisulfite sequencing at the STAT3 binding site within the
GFAP locus (Fig. 5A, indicated by black bidirectional ar-
rows) by using wild-type or mutant MECP2-expressing
neurospheres. Nevertheless, the MeCP2 binding sites in
the GFAP gene were similarly hypermethylated in both
wild-type and mutantMECP2-expressing neural stem cells
differentiated from the four hiPSC lines (Fig. 5C). These
findings signify that aberrant GFAP gene expression in
neural stem cells containing truncated MeCP2 is not
caused by changes in DNA methylation status (i.e., hypo-
methylation) within the genomic region encompassing the
STAT3 binding site. Instead, the aberrant gene expression
may be due to alterations in the amount of MeCP2 that
Fig. 5 MeCP2 binding analysis and DNA methylation status of the GFAP promoter region. (A) Schematic representation of the hGFAP
genomic locus. ChIP/qPCR analysis was performed for the genomic regions (i.e., the STAT3 binding site and GFAP exon 1) indicated by the
blue bidirectional arrows. Bisulfite sequencing was performed for the genomic region indicated by the black bidirectional arrows. (B) MeCP2
binding to the STAT3 binding site within the GFAP promoter region was quantified via ChIP/qPCR analysis by using an anti-MeCP2 antibody
in neural cells differentiated from RTT-hiPSC lines. (C) Methylation frequencies of (1) the CpG site within the STAT3 recognition sequence
and (2) seven other CpG sites around this sequence were analyzed in hiPSC-derived neurosphres via bisulfite sequencing
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binds to the STAT3 binding site within the GFAP pro-
moter and the hGFAP exon1.
Discussion
Female RTT patients display somatic mosaicism, because
the MECP2 gene is located on the X chromosome and
undergoes random XCI. Here, we successfully generated
two kinds of isogenic RTT-hiPSC lines that expressed only
the wild-type or the mutant MECP2 allele from the same
RTT patient. So far, several groups have demonstrated
disease modeling of RTT by using patient-specific
hiPSCs [19,21-24]. However, some of these studies were
conducted by comparisons between mutant hiPSCs de-
rived from RTT patients and control hiPSCs derived
from healthy subjects [19].
Regarding hiPSC technologies, clonal variations caused
by donor differences and cell types of origin reportedly
determine the differentiation potential of hiPSC clones.
Hence, isogenic controls genetically engineered by using
ZFN, TALEN or CRISPR-Cas9 systems are required for
precise disease modeling with patient-specific hiPSCs
[40]. Our isogenic RTT-hiPSC system has two significant
advantages over these previous systems. First, our system
allows clonal generation of hiPSCs expressing either
wild-type or mutant MeCP2 protein. Second, the gener-
ated hiPSCs are isogenic without genetic engineering. By
utilizing our homogenous RTT-hiPSC populations, we
were able to show that global gene expression patterns
were distinctly different between wild-type MeCP2-cells
and mutant MeCP2-expressing cells in terms of both
neurospheres and differentiated neural stem cells. Al-
though MeCP2 was weakly expressed in undifferentiated
wild-type hiPSCs, significant differences in gene expres-
sion profiles were not observed among the four hiPSC
lines. These results suggest that the MeCP2 primarily
functions in cells already committed to a neural lineage.
We also found increased proportions of astrocytes
among mutant MeCP2-expressing neural cells compared
with wild-type MeCP2-expressing neural cells. Other in-
vestigators similarly documented MeCP2 expression in
glial cells, including astrocytes [41], implying that glial
MeCP2 might play a distinct role in the maintenance of
neuronal functions, such as neuronal maturation and/or
dendritic arborization [42]. Although previous studies
showed that a conditional MeCP2 knockout mouse (which
lacked MeCP2 expression in mature neurons) displayed a
RTT-like neurological phenotype, mutant astrocytes de-
rived from this model mouse failed to support normal
dendritic arborization of either wild-type or mutant neu-
rons [30]. Furthermore, mutant MECP2-expressing astro-
cytes differentiated from RTT-hiPSCs apparently had
significant effects on wild-type neurons [26]. Intriguingly,
another study in mice showed that the MeCP2-deficient
state can spread between astrocytes via gap junctions [43].
The current investigation did not examine dendritic
phenotypes in neurons derived from RTT-hiPSCs. How-
ever, our model may be useful for mixed culture experi-
ments (i.e., wild-type MECP2-expressing neurons and
mutant MECP2-expressing astrocytes) to distinguish
cell-autonomous from non-cell-autonomous effects in
RTT patient-derived neural cells. Additionally, we dem-
onstrated that astrocytic marker genes, particularly
GFAP, were aberrantly expressed under conditions of
MeCP2 deficiency due to the deregulation of transcription,
and we employed ChIP and bisulfite sequencing analyses
to show induction of GFAP expression in RTT-hiPSC-
derived neural cells caused by the absence of direct bind-
ing of mutant MeCP2 to the GFAP gene. Hence, mutant
MeCP2 may contribute to the excessive differentiation of
GFAP-positive astrocytes.
Several groups reported that human female RTT patients
present with microcephalic brains, as do male and female
Rett syndrome model mice [44-46]. Moreover, analysis of
postmortem brain tissue from RTT patients revealed in-
creased GFAP protein expression in the RTT brain [32].
Consistent with these results, we anticipate that the brains
of RTT patients will exhibit a larger than normal percent-
age of astrocytes. Thus, astrocytes differentiated from RTT
patient-derived, mutant MECP2-expressing hiPSC lines
may be useful for drug development for RTT therapy, be-
cause some drugs for mental disorders (e.g., antidepres-
sants) affect not only neurons, but also activate astrocytes.
The activated astrocytes then go on to carry out specific
functions that result in the reactivation of cortical plasti-
city, potentially leading to the readjustment of abnormal
neural networks [47,48].
This study aimed to clarify the involvement of epigen-
etic and environmental cues in the neural development
of RTT-MZ twins (patients RS1 and RS2) with differing
symptom severity. Although we successfully generated
hiPSCs from both patients, no significant differences in
mutant MeCP2 phenotypes were observed between RS1
and RS2 cells. These results suggest that epigenetic and
environmental cues might work together to affect the
neural phenotypes of RTT patients. Another possibility
is that skewed XCI occurs in the CNS in RTT patients.
Although we previously reported that biased XCI does
not take place in the other somatic cells (i.e., skin, blood,
and hair) of these patients [27], biased XCI in the CNS
may underlie the discrepancy in symptom severity be-
tween isogenic RTT-MZ twin patients.
Conclusions
In summary, we successfully generated two sets of iso-
genic RTT-hiPSC lines that expressed only the wild-type
or the mutant MECP2 allele from the same RTT patient,
and revealed that abnormal astrocytic differentiation is in-
volved in RTT pathogenesis. Specifically, we used hiPSC
Andoh-Noda et al. Molecular Brain  (2015) 8:31 Page 7 of 11
technology to show that (1) MeCP2 protein deficiency re-
sults in dysregulation of GFAP expression in mutant
MECP2-expressing neural cells, and (2) an increased num-
ber of astrocytes are differentiated from RTT-hiPSC-
derived neural stem cells carrying mutant vs. wild-type
MECP2.
Materials and methods
Isolation of skin fibroblasts and generation of hiPSCs
A skin-punch biopsy from a single pair of 10-year-old
Japanese MZ twins with RTT (patients RS1 and RS2)
[27] was performed with written informed consent from
their parents. The obtained fibroblasts were used to es-
tablish the four hiPSC lines discussed above. The study
protocol was reviewed and approved by the Research
Ethics Committees of Keio University (Approval No.
20080016) and the University of Yamanashi (Approval
Nos. 523 and 699). This study was conducted in accord-
ance with the principles expressed in the Declaration of
Helsinki.
A standard retrovirus method was used to establish
the hiPSCs. The maintenance of fibroblasts, lentiviral
production, retroviral production, infection, stem cell
culture, and characterization of hiPSCs was conducted
as described previously [17].
Sample collection and DNA isolation
All peripheral blood, skin fibroblasts, and hiPSC samples
used in this study were obtained from RTT-MZ patients
whose parents gave informed consent for medical re-
search at the University of Yamanashi and Keio Univer-
sity Hospital. DNA from lymphocytes, skin fibroblasts,
and hiPSCs was extracted with the DNeasy Blood and
Tissue Kit (QIAGEN) according to the manufacturer’s
instructions.
XCI analysis
XCI patterns were obtained in the extracted DNA by
using a methylation-specific PCR-based method. Bisul-
fite treatment of genomic DNA followed by PCR was
performed as previously described [28]. Briefly, DNA
was treated with sodium bisulfite, and the treated DNA
was amplified via PCR by using two primer sets (one for
the methylated inactive X chromosome, and the other
for the unmethylated active X chromosome). The primer
sets were designed within the CpG island (exon 1) of the
HUMARA gene located at Xq11-a12. The PCR products
were mixed with a size standard and separated on an
ABI 310 DNA Sequencer equipped with Genescan
Software (Applied Biosystems).
Teratoma assay
Teratoma formation was assessed by injecting hiPSCs
into the testes of 8-week-old NOD.CB17-Prkdcscid/J mice
(OYC International, Inc.), as previously described [49].
Eight weeks after hiPSC transplantation, tumors were
dissected and fixed with phosphate buffered saline (PBS)
containing 4% formaldehyde. Paraffin-embedded tissue
was sectioned and stained with hematoxylin & eosin.
Images were obtained by using a BZ-9000 microscope
(Keyence).
Karyotyping of hiPSCs
Standard G-banding analysis was performed in the four
hiPSC lines (RS1-52 M, RS1-61P, RS2-65 M, and RS2-
62P) to rule out the possibility of abnormal karyotypes
that can occur during the generation of hiPSCs.
In vitro differentiation of hiPSCs
Neural differentiation of hiPSCs was performed as de-
scribed previously [50], except that epidermal growth
factor and Noggin were omitted from the culture system
(Matsumoto et al., manuscript in submission). The
hiPSCs were plated onto the bottom of T75 flasks (Nun-
clon) and maintained for 14 days. Neurospheres were re-
peatedly passaged by dissociation into single cells,
followed by culture in the same manner. Neurospheres
were differentiated into neural cells by using an adhesion
culture method without FGF-2, and then subjected to
qPCR and immunostaining analysis. Typically, neuro-
spheres between passages 3 and 10 were used for the
analysis. RNA samples were collected on day 14 of neu-
rosphere culture from an arbitrary number of cells. For
terminal differentiation, neurospheres were cultured in
1 × B27 medium, dissociated neural precursor cells
allowed to adhere to poly-L-ornithine-/fibronectin-
coated coverslips and then cultured for 30–32 days.
RNA was then isolated from terminally differentiated
neurospheres. Alternatively, the differentiated cells were
immunostained with primary antibodies against βIII-
tubulin and GFAP. Approximately 1 × 105 neural stem
cells were plated onto 14-mm glass coverslips for immu-
nostaining of differentiated neural cells, and ~ 1.2 × 106
neural stem cells were plated onto a well using 6-well
plate for RNA isolation from differentiated neural cells.
For long-term neural differentiation, mouse astrocytes
obtained from E16.5 ICR mice were utilized with a cell
culture insert system (Falcon® product #353102). RNA
samples were obtained from iPSCs, neurospheres, and
neuronal cells at passages 12–20, passages 3–9 (day 14),
and day 30–32, respectively.
Immunocytochemical analysis of hiPSCs and neural cells
differentiated from hiPSCs
Cells were fixed with PBS containing 4% paraformalde-
hyde for 30 min at room temperature and incubated
with primary antibodies against the following proteins:
MeCP2 (1:200, Cell Signaling Technology), phalloidin
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(1:2000, Dyomics), NANOG (1:500, CosmoBio), OCT4
(1:200, Santa Cruz Biotechnology, Inc.), TRA-1-60
(1:1000, Millipore), TRA-1-81 (1:1000, Millipore), βIII-
tubulin (1:2000, Sigma Chemical Co.), MAP2 (1:250,
Sigma Chemical Co.), and GFAP (1:1000, Invitrogen).
They were then washed with PBS and incubated with an
Alexa Fluor 488-, Alexa Fluor 555-, or Alexa Fluor 647-
conjugated secondary antibody (1:500, Invitrogen), as
appropriate. Images were obtained using an Axioplan 2
microscope (Carl Zeiss). The number of GFAP-positive
cells was counted among 100 Hoechst-positive cells for
each experiment (n = 5).
Microarray analysis
For microarray analysis, RNA quality was assessed by
using a 2100 Bioanalyzer (Agilent Technologies). Total
RNA (100 ng) was reverse transcribed, biotin- labeled,
and hybridized to a GeneChip® Human Genome U133
plus 2.0 Array (Affymetrix). The array was subsequently
washed and stained in a Fluidics Station 450 (Affymetrix),
as instructed by the manufacturer. The microarrays were
scanned by using a GeneChip® Scanner 3000 (Affymetrix),
and the raw image files were converted into normalized
signal intensity values by using the MAS 5.0 algorithm.
Next, targets were selected that (a) were “present” in
at least one of the eight arrays analyzed, and (b) had a
probe intensity of ≥ 50. In total, 23,463 targets were
identified from this initial screen. The normalized logs
were hierarchically clustered based on uncentered cor-
relation with complete linkage by using Cluster 3.0 Soft-
ware [51]. The PCA plot was generated by using TIGR
MeV (Multiple Experimental Viewer) Software [52]. The
three-dimensional image of the PCA plot and the scatter
plot were generated by using GeneSpring GX Software
(ver. 12.6.1).
Quantitative reverse transcription PCR (qPCR) assay
Total cellular RNA was extracted by using the TRIzol
Reagent® (Life Technologies), the RNase-Free DNase
Set (QIAGEN), and the RNeasy® Mini Kit (QIAGEN).
Next, cDNA synthesis was performed by using the
SuperScript III First-Strand Synthesis System for RT-
PCR (Life Technologies) with oligo-dT primers accord-
ing to the manufacturer’s guidelines. Real-time RT-PCR
was then performed on a ABI PRISM® 7900HT Sequence
Detection System (Applied BioSystems) by using SYBR
Premix ExTaq Tli RNaseH Plus (Takara). The qPCR amp-
lification was performed by using the following primers:
GFAP-forward (5’-TGTGAGGCAGAAGCTCCAGGATG
A-3’) and GFAP-reverse (5’- AGGGTGGCTTCATCTGC
TTCCTGT-3’); S100β-forward (5’-GTGGCCCTCATCGA
CGTTTT-3’) and S100β-reverse (5’-ACCTCCTGCTCTT
TGATTTCCTCT-3’); TUBB3-forward (5’-ATTTCATCT






Relative gene expression levels of GFAP, S100β, TUBB3,
and MAP2 were normalized to ACTB expression and
standardized by the RS1-52 M value, which was set to 1.
ChIP assay
Nuclei were obtained from neurospheres derived from
each hiPSC line. ChIP was performed with antibodies
against MeCP2 (Cell Signaling Technology), as described
previously [53], with the following modifications. Neuro-
spheres were crosslinked with 1% formaldehyde for
10 min to yield crosslinked chromatin. They were then
incubated with glycine at a final concentration of
200 mM for another 5 min, and stored at −80°C until
use. The lysed nuclear pellets were sonicated six times
with a 30-sec ON, 60-sec OFF cycle by using a Bioruptor®
Sonicator (Diagenode, Inc.). The crosslinked chromatin
was subsequently eluted from magnetic beads (Dynabeads®
M-280 Sheep anti-Rabbit IgG; Life Technologies). Co-
immunoprecipitated DNA was detected via qPCR by
using the following primers: STAT3 binding site-forward
(5’-TCATGCCCAGTGAATGACTC-3’) and STAT3 bind-
ing site-reverse (5’-AGATGCCAGGCTGTCAGG-3’); and
hGFAP exon1-forward (5’-AGAGCAGGATGGAGAGGA
GA-3’) and hGFAP exon1-reverse (5’- CCTTGAAGCC
AGCATTGAGT-3’).
Bisulfite sequencing analysis
Sodium bisulfite treatment of genomic DNA was per-
formed by using the Methylamp DNA Modification Kit
(Epigentek) according to the manufacturer’s instructions. A
region in the GFAP promoter region containing the STAT3
binding site was amplified from bisulfite-treated genomic
DNA via PCR with the following forward and reverse
primers: hGFAP promoter-forward (5’-TTGGGGAGGAG
GTAGATAGTTAGGTTTT-3’) and hGFAP promoter-
reverse (5’-CATCCCCTAATCCCCTTTCCTAAA-3’). PCR
products were cloned into the pT7Blue vector (Novagen),
and at least 12 randomly selected clones were sequenced.
Statistical analysis
All quantifiable data are expressed as the means ± the
standard deviation of the mean. The statistical signifi-
cance of differences between conditions was analyzed
by using Student’s t-test and Welch’s t-test. In all
cases, p values of < 0.05 were considered statistically
significant.
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Additional files
Below is the link to the electronic supplementary material.
Additional file 1: Characterization of RTT-hiPSCs. (A) Isogenic RTT-
hiPSCs demonstrate similar embryonic stem cell-like morphology and
stain positively for the pluripotency markers, NANOG, OCT4, and TRA-1-
81. Scale bar for phase contrast images, 500 μm; scale bar for NANOG,
OCT4, and TRA-1-81 immunostaining, 50 μm. (B) Representative images
of teratomas generated in immunodeficient mice that received an
intratesticular injection of RTT-hiPSCs. The teratomas corresponded to
well-defined, cystic tumors containing tissues of all three germ layers
(endoderm, mesoderm, and ectoderm). Scale bar, 100 μm. (C) Images
of RTT-hiPSC karyotypes. (PDF 246 kb)
Additional file 2: Three-dimensional image of the PCA. The
clustering pattern of the cells (hiPSCs vs. neural cells (N) was dependent
on the MECP2 expression pattern and the presence or absence of MeCP2
protein.
Additional file 3: Gene expression analysis of iPSCs. (A) Global gene
expression/comparative microarray analyses of undifferentiated hiPSCs
and differentiated neural cells. N denotes neural cells. (B) Comparison of
NR3C1 gene expression in hiPSCs and differentiated neural cells by qPCR.
Relative gene expression was normalized by ACTB gene expression.
Primer sets are listed in Additional file 5. Data were analyzed by Student’s
t-test and Welch’s t-test (*p < 0.05).
Additional file 4: Properties of neural stem cells derived from
RTT-hiPSCs. (A) Diameter (n = 3) and (B) number of neurospheres (n = 16)
derived from RTT-hiPSCs at 7 days in vitro. (C) The mRNA expression levels
of the neural stem cell markers, NESTIN (NES) and SOX1, were quantified in
RTT hiPSC-derived neurospheres by qPCR. Each value was normalized by
comparison with ACTB expression and standardized by the value for the
wild-type MECP2-expressing RS1-52 M clone, which was set to 1 (n = 4).
Primer sets are listed in Additional file 5. Data were analyzed by Student’s
t-test and Welch’s t-test (*p < 0.05).
Additional file 5: List of primers used in Additional file 3 and 4.
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